RecruitingLiver MetastasesStereotactic Body Radiation TherapyMRI-guided Treatment
OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided Stereotactic Body Radiation Therapy (SBRT) treatment of bowel and liver metastases, respectively. Eligible participants will be on study for up to 12 months.
Sponsor: University of Wisconsin, Madison
You may qualify if…
- ✓ Have a diagnosis of histologically confirmed or clinically suspected metastatic cancer to the liver.
- ✓ Participant must be a candidate for SBRT to at least one intrahepatic lesion but no more than 6 intrahepatic lesions.
- ✓ Participant must be a candidate for treatment on the ViewRay treatment unit. Must be screened to rule out implants and devices that are not MRI compatible.
- ✓ Be willing and able to provide written informed consent.
- ✓ Participants may be therapy-naïve or have had prior systemic therapy up to two weeks prior to study entry.
- ✓ No active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS involvement must meet all of the following to be eligible:
- ✓ At least 28 days from prior definitive treatment of their CNS disease by surgical resection, SBRT or Whole Brain Radiation Therapy (WBRT) at the time of registration
- ✓ AND asymptomatic and off systemic corticosteroids and/or enzyme-inducing antiepileptic medications for brain metastases for \>14 days prior to registration.
You may not qualify if…
- ✕ Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the initiation of SBRT.
- ✕ History of a second invasive cancer in the last 3 years (except for appropriately treated low-risk prostate cancer, treated non-melanoma skin cancer, appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of breast appropriately treated in situ/early stage cervical/endometrial cancer.
- ✕ Has an active infection requiring systemic therapy.
- ✕ Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- ✕ Has known psychiatric or substance abuse disorders that would interfere with follow up scans or visits.
- ✕ Has a primary tumor histology of germ cell tumor, leukemia, or lymphoma.
- ✕ Has a primary liver cancer such as cholangiocarcinoma or hepatocellular carcinoma.
- ✕ Has had prior radiation therapy that significantly overlaps with the liver.
Where it's recruiting
Wisconsin
Madison
Source: ClinicalTrials.gov · NCT04020276 · last updated 2026-06-11